Rain Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.rainoncology.com
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
- Conditions
- Advanced Solid TumorUrothelial Carcinoma BladderMelanomaGastric CancerCDKN2ANSCLCHNSCCRenal Cell CarcinomaMesotheliomaPancreas Adenocarcinoma
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Rain Oncology Inc
- Registration Number
- NCT06090318
A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects
- Conditions
- Cardiac Repolarization
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05758818
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
Milademetan in Advanced/Metastatic Solid Tumors
- Conditions
- Solid TumorsHead and Neck CarcinomaCholangiocarcinomaSarcomaLung AdenocarcinomaOvarian CarcinomaGastric CancerBladder Urothelial CarcinomaStomach AdenocarcinomaBreast Cancer Invasive
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 40
- Registration Number
- NCT05012397
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 175
- Registration Number
- NCT04979442
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Miami Hospital & Clinics - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
- Conditions
- EGFR Exon 20 Insertion MutationHER2-activating MutationERBB FusionNSCLC Stage IIIBNRG1 FusionNSCLC, Stage IVNSCLC, Stage IIICNSCLC, Recurrent
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 41
- Registration Number
- NCT03805841
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Providence Cancer Institute, Portland, Oregon, United States
🇺🇸University of California San Francisco, Helen Diller Cancer Center, San Francisco, California, United States
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Non-small Cell Lung CancerNSCLCNon-squamous NSCLC
- Interventions
- Drug: TH-4000 (Tarloxotinib)
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 21
- Registration Number
- NCT02454842
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, United States
🇦🇺Peter MacCullum, Melbourne, Victoria, Australia
Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
- Conditions
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Interventions
- Drug: TH-4000 (Tarloxotinib)
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 30
- Registration Number
- NCT02449681
- Locations
- 🇺🇸
University of Southern California-Norris, Los Angeles, California, United States
🇺🇸Walter Reed National Military Cancer Center, Bethesda, Maryland, United States
🇺🇸Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tennessee, United States